Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
48 studies found for:    "Pars planitis"
Show Display Options
Rank Status Study
21 Completed A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
Conditions: Uveitis, Posterior;   Uveitis, Intermediate;   Panuveitis
Interventions: Drug: Placebo;   Drug: LX211
22 Completed A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
Conditions: Uveitis, Posterior;   Uveitis, Intermediate;   Panuveitis
Interventions: Drug: Placebo;   Drug: LX211
23 Completed
Has Results
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
Condition: Uveitis
Interventions: Drug: Adalimumab;   Drug: Prednisone;   Drug: Placebo
24 Completed
Has Results
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
Condition: Uveitis
Interventions: Biological: Adalimumab;   Drug: Prednisone;   Drug: Placebo
25 Completed Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
Conditions: Uveitis;   Posterior Uveitis;   Panuveitis
Intervention: Drug: AEB071
26 Enrolling by invitation The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease
Conditions: Uveitis;   Vasculitis;   Ocular Inflammatory Disease
Intervention:
27 Completed Vascular Endothelial Growth Factor (VEGF) in Uveitis
Conditions: Macular Edema, Cystoid;   Uveitis
Intervention:
28 Completed Leflunomide to Treat Uveitis
Condition: Uveitis
Intervention: Drug: Leflunomide
29 Recruiting Ustekinumab (STELARA ) for the Treatment of Active Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Ustekinumab
30 Terminated Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)
Condition: Chronic Uveitis
Intervention: Biological: Gevokizumab
31 Terminated An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
Condition: Uveitis
Intervention: Drug: Dose 2 gevokizumab
32 Terminated Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
Condition: Uveitis
Interventions: Drug: Placebo;   Drug: Dose 1 gevokizumab;   Drug: Dose 2 gevokizumab
33 Terminated Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
Condition: Uveitis
Interventions: Drug: Placebo;   Drug: Dose 1 gevokizumab;   Drug: Dose 2 gevokizumab
34 Completed
Has Results
Topical Interferon Gamma for Macular Edema Secondary to Uveitis
Conditions: Anterior Uveitis;   Uveitis
Intervention: Drug: Interferon Gamma-1b
35 Withdrawn Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
Condition: Uveitis
Intervention: Biological: AIN457
36 Active, not recruiting A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
Condition: Uveitis
Intervention: Drug: adalimumab
37 Recruiting Immunogenetic Mechanisms in Behcet's Disease
Conditions: Behcet's Disease;   Uveitis
Intervention:
38 Terminated Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
Condition: Uveitis
Interventions: Biological: AIN457;   Biological: Placebo
39 Terminated
Has Results
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
Condition: Uveitis
Interventions: Drug: AIN457;   Drug: Placebo
40 Terminated
Has Results
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
Condition: Non-infectious Uveitis
Interventions: Drug: AIN457;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-48) Show next page of results    Last Page
Indicates status has not been verified in more than two years